-
公开(公告)号：US07687461B2
公开(公告)日：2010-03-30
申请号：US10963994
申请日：2004-10-12
申请人： John R. Desjarlais , Anton Filikov , Paul Michael Steed , Jonathan Zalevsky , David Edmund Szymkowski
发明人： John R. Desjarlais , Anton Filikov , Paul Michael Steed , Jonathan Zalevsky , David Edmund Szymkowski
IPC分类号： A61K38/19 , C07K14/525
CPC分类号： C07K14/525 , A61K38/191 , C07K14/70575
摘要： The invention relates to novel proteins with TNF-alpha antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-alpha related disorders.
摘要翻译： 本发明涉及具有TNF-α拮抗剂活性的新型蛋白质和编码这些蛋白质的核酸。 本发明还涉及新型蛋白质在治疗TNF-α相关疾病中的用途。
-
2.发明授权公开(公告)号：US07662367B2
公开(公告)日：2010-02-16
申请号：US11472864
申请日：2006-06-22
申请人： John R. Desjarlais , Paul Michael Steed , Jonathan Zalevsky , David Edmund Szymkowski , David F. Carmichael
发明人： John R. Desjarlais , Paul Michael Steed , Jonathan Zalevsky , David Edmund Szymkowski , David F. Carmichael
CPC分类号： A61K38/191 , C07K14/525
摘要： The invention relates to a pharmaceutical composition comprising a variant TNF-α protein that inhibits the activity of soluble TNF-α while substantially maintaining the activity of transmembrane TNF-α a buffer and a tonicity agent wherein said composition has a pH from approximately 5.0 to 8.0.
摘要翻译： 本发明涉及一种药物组合物，其包含抑制可溶性TNF-α活性的变体TNF-α蛋白，同时基本上保持跨膜TNF-α的缓冲液和张力剂的活性，其中所述组合物的pH为约5.0至8.0 。
-
3.发明申请Pharmaceutical Compositions for the Treatment of TNF-Alpha Related Disorders 审中-公开用于治疗TNF-α相关疾病的药物组合物公开(公告)号：US20100222272A1
公开(公告)日：2010-09-02
申请号：US12693225
申请日：2010-01-25
申请人： John R. Desjarlais , Paul Michael Steed , Jonathan Zalevsky , David Edmund Szymkowski , David F. Carmichael
发明人： John R. Desjarlais , Paul Michael Steed , Jonathan Zalevsky , David Edmund Szymkowski , David F. Carmichael
CPC分类号： A61K38/191
摘要： The invention relates to a pharmaceutical composition comprising a variant TNF-α protein that inhibits the activity of soluble TNF-α while substantially maintaining the activity of transmembrane TNF-α, a buffer, and a tonicity agent, wherein said composition has a pH from approximately 5.0 to 8.0.
摘要翻译： 本发明涉及一种药物组合物，其包含抑制可溶性TNF-α活性的变体TNF-α蛋白，同时基本上保持跨膜TNF-α的活性，缓冲液和张力剂，其中所述组合物的pH值约为 5.0〜8.0。
-
4.发明授权Protein based TNF-α variants for the treatment of TNF-α related disorders 有权用于治疗TNF-α相关疾病的基于蛋白质的TNF-α变体公开(公告)号：US07446174B2
公开(公告)日：2008-11-04
申请号：US11108001
申请日：2005-04-14
CPC分类号： A61K38/191 , C07K14/525
摘要： The invention relates to novel proteins with TNF-α antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-α related disorders.
摘要翻译： 本发明涉及具有TNF-α拮抗剂活性的新型蛋白质和编码这些蛋白质的核酸。 本发明还涉及新型蛋白质在治疗TNF-α相关疾病中的用途。
-
5.发明申请公开(公告)号：US20080187509A1
公开(公告)日：2008-08-07
申请号：US11472864
申请日：2006-06-22
申请人： John R. Desjarlais , Paul Michael Steed , Jonathan Zalevsky , David Edmund Szymkowski , David F. Carmichael
发明人： John R. Desjarlais , Paul Michael Steed , Jonathan Zalevsky , David Edmund Szymkowski , David F. Carmichael
IPC分类号： A61K38/19
CPC分类号： A61K38/191 , C07K14/525
摘要： The invention relates to a pharmaceutical composition comprising a variant TNF-α protein that inhibits the activity of soluble TNF-α while substantially maintaining the activity of transmembrane TNF-α, a buffer, and a tonicity agent, wherein said composition has a pH from approximately 5.0 to 8.0.
摘要翻译： 本发明涉及一种药物组合物，其包含抑制可溶性TNF-α活性的变体TNF-α蛋白，同时基本上保持跨膜TNF-α的活性，缓冲液和张力剂，其中所述组合物的pH值约为 5.0〜8.0。
-
公开(公告)号：US07141365B2
公开(公告)日：2006-11-28
申请号：US09861038
申请日：2001-05-18
CPC分类号： G01N33/5008 , A01K2217/05 , C07K14/47 , C07K14/4727 , G01N33/502 , G01N33/5044 , G01N33/68 , G01N2333/4725
摘要： Methods and compositions for modulating mucin secretion by respiratory system cells are provided. In the subject methods, an effective amount of an hCLCA2 (or homolog thereof) modulatory agent is contacted with the cell to modulate mucin secretion, e.g., decrease or increase mucin secretion, by the cell. The subject methods find use in a variety of different applications, including the treatment of disease conditions associated with respiratory system mucin secretion, e.g., mucin hyper- or hyposecretion. Also provided are methods of screening for respiratory system mucin secretion modulatory agents. Finally, mCLCA4 and non-human homologs thereof, as well as nucleic acid compositions encoding the same, are provided.
摘要翻译： 提供了调节呼吸系统细胞粘蛋白分泌的方法和组合物。 在本方法中，有效量的hCLCA2（或其同系物）调节剂与细胞接触以调节细胞的粘蛋白分泌，例如降低或增加粘蛋白分泌。 主题方法可用于各种不同的应用，包括治疗与呼吸系统粘蛋白分泌相关的疾病状况，例如粘蛋白高或低分泌。 还提供了筛选呼吸系统粘蛋白分泌调节剂的方法。 最后，提供了mCLCA4及其非人类同系物，以及编码其的核酸组合物。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.016 秒)
